Logo image of UBM.MI

ULISSE BIOMED SPA (UBM.MI) Stock Fundamental Analysis

Europe - Euronext Milan - BIT:UBM - IT0005451213 - Common Stock

0.8 EUR
0 (0%)
Last: 12/8/2025, 7:00:00 PM
Fundamental Rating

3

Overall UBM gets a fundamental rating of 3 out of 10. We evaluated UBM against 81 industry peers in the Biotechnology industry. UBM has a bad profitability rating. Also its financial health evaluation is rather negative. UBM is valued quite expensive, but it does show an excellent growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year UBM has reported negative net income.
UBM had a negative operating cash flow in the past year.
UBM had negative earnings in 4 of the past 5 years.
In the past 5 years UBM always reported negative operating cash flow.
UBM.MI Yearly Net Income VS EBIT VS OCF VS FCFUBM.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 -2M -4M

1.2 Ratios

With a Return On Assets value of -21.16%, UBM perfoms like the industry average, outperforming 51.81% of the companies in the same industry.
UBM has a better Return On Equity (-24.96%) than 62.65% of its industry peers.
Industry RankSector Rank
ROA -21.16%
ROE -24.96%
ROIC N/A
ROA(3y)-18.88%
ROA(5y)-10.46%
ROE(3y)-21.54%
ROE(5y)-11.74%
ROIC(3y)N/A
ROIC(5y)N/A
UBM.MI Yearly ROA, ROE, ROICUBM.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for UBM so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
UBM.MI Yearly Profit, Operating, Gross MarginsUBM.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K -10K

More info and screens

3

2. Health

2.1 Basic Checks

UBM does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for UBM has been increased compared to 1 year ago.
Compared to 5 years ago, UBM has more shares outstanding
UBM has a better debt/assets ratio than last year.
UBM.MI Yearly Shares OutstandingUBM.MI Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
UBM.MI Yearly Total Debt VS Total AssetsUBM.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

Based on the Altman-Z score of 1.57, we must say that UBM is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of UBM (1.57) is better than 65.06% of its industry peers.
A Debt/Equity ratio of 0.05 indicates that UBM is not too dependend on debt financing.
UBM's Debt to Equity ratio of 0.05 is fine compared to the rest of the industry. UBM outperforms 67.47% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Altman-Z 1.57
ROIC/WACCN/A
WACC8%
UBM.MI Yearly LT Debt VS Equity VS FCFUBM.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 10M 20M

2.3 Liquidity

A Current Ratio of 2.15 indicates that UBM has no problem at all paying its short term obligations.
UBM has a Current ratio of 2.15. This is comparable to the rest of the industry: UBM outperforms 42.17% of its industry peers.
A Quick Ratio of 1.07 indicates that UBM should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.07, UBM is doing worse than 67.47% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.15
Quick Ratio 1.07
UBM.MI Yearly Current Assets VS Current LiabilitesUBM.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M

More info and screens

7

3. Growth

3.1 Past

UBM shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 65.69%, which is quite impressive.
UBM shows a strong growth in Revenue. In the last year, the Revenue has grown by 119.93%.
UBM shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 135.06% yearly.
EPS 1Y (TTM)65.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%29.47%
Revenue 1Y (TTM)119.93%
Revenue growth 3Y40.55%
Revenue growth 5Y135.06%
Sales Q2Q%42.57%

3.2 Future

The Earnings Per Share is expected to grow by 26.08% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 59.01% on average over the next years. This is a very strong growth
EPS Next Y84.6%
EPS Next 2Y36.32%
EPS Next 3Y26.08%
EPS Next 5YN/A
Revenue Next Year-19.59%
Revenue Next 2Y26.82%
Revenue Next 3Y59.01%
Revenue Next 5YN/A

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
UBM.MI Yearly Revenue VS EstimatesUBM.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 1M 2M 3M 4M 5M
UBM.MI Yearly EPS VS EstimatesUBM.MI Yearly EPS VS EstimatesYearly EPS VS Estimates 2025 2026 2027 0 -0.01 -0.02 -0.03

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for UBM. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for UBM. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
UBM.MI Price Earnings VS Forward Price EarningsUBM.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
UBM.MI Per share dataUBM.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 0.4 0.6 0.8

4.3 Compensation for Growth

A more expensive valuation may be justified as UBM's earnings are expected to grow with 26.08% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.32%
EPS Next 3Y26.08%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for UBM!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

ULISSE BIOMED SPA

BIT:UBM (12/8/2025, 7:00:00 PM)

0.8

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners0.58%
Inst Owner ChangeN/A
Ins Owners33.36%
Ins Owner ChangeN/A
Market Cap20.41M
Revenue(TTM)925.90K
Net Income(TTM)-5.30M
Analysts84
Price Target1.52 (90%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)20.65%
PT rev (3m)36.7%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)9.76%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 22.04
P/FCF N/A
P/OCF N/A
P/B 0.96
P/tB 7.09
EV/EBITDA N/A
EPS(TTM)-0.2
EYN/A
EPS(NY)-0.03
Fwd EYN/A
FCF(TTM)-0.11
FCFYN/A
OCF(TTM)-0.1
OCFYN/A
SpS0.04
BVpS0.83
TBVpS0.11
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -21.16%
ROE -24.96%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-18.88%
ROA(5y)-10.46%
ROE(3y)-21.54%
ROE(5y)-11.74%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 3.07%
Cap/Sales 10.07%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.15
Quick Ratio 1.07
Altman-Z 1.57
F-Score5
WACC8%
ROIC/WACCN/A
Cap/Depr(3y)25.49%
Cap/Depr(5y)134.9%
Cap/Sales(3y)106.09%
Cap/Sales(5y)137.8%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)65.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%29.47%
EPS Next Y84.6%
EPS Next 2Y36.32%
EPS Next 3Y26.08%
EPS Next 5YN/A
Revenue 1Y (TTM)119.93%
Revenue growth 3Y40.55%
Revenue growth 5Y135.06%
Sales Q2Q%42.57%
Revenue Next Year-19.59%
Revenue Next 2Y26.82%
Revenue Next 3Y59.01%
Revenue Next 5YN/A
EBIT growth 1Y23.96%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year80.83%
EBIT Next 3Y25.99%
EBIT Next 5YN/A
FCF growth 1Y-78.81%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-89.7%
OCF growth 3YN/A
OCF growth 5YN/A

ULISSE BIOMED SPA / UBM.MI FAQ

Can you provide the ChartMill fundamental rating for ULISSE BIOMED SPA?

ChartMill assigns a fundamental rating of 3 / 10 to UBM.MI.


Can you provide the valuation status for ULISSE BIOMED SPA?

ChartMill assigns a valuation rating of 1 / 10 to ULISSE BIOMED SPA (UBM.MI). This can be considered as Overvalued.


What is the profitability of UBM stock?

ULISSE BIOMED SPA (UBM.MI) has a profitability rating of 1 / 10.


What is the financial health of ULISSE BIOMED SPA (UBM.MI) stock?

The financial health rating of ULISSE BIOMED SPA (UBM.MI) is 3 / 10.